摘要
目的探讨老年糖尿病患者CYP2C19基因多态性与氯吡格雷抵抗发生的相关性。方法72例初步诊断为急性冠脉综合征、糖尿病的老年（〉65岁）患者纳入本研究，给予阿司匹林及氯吡格雷口服，并经血栓弹力图检测氯吡格雷抑制率，氯吡格雷抑制率〈50％定义为氯吡格雷抵抗。采用基因芯片检测技术检测CYP2C19基因多态性，进一步探讨CYP2C19基因多态性与氯吡格雷抵抗发生的相关性。结果72例患者中，纯合子强代谢型（CYP2C19★1／★1）19例（26．4％），杂合子强代谢型（CYP2C19★1／★2，CYP2C19六1／★3）36例（50％），弱代谢型（CYP2C19-k2／★2，CYP2C19六2／六3）17例（23．6％），三种代谢组中出现氯吡格雷抵抗的概率分别为36．8％、52．8％和82．4％，差别有统计学意义。结论老年糖尿病患者CYP2C19基因多态性与氯吡格雷抵抗的发生具有相关性。
Objective To investigate the relation between CYP2C19 polymorphism and effect of clopidogrel resistance（CR） among the elderly patients with type Ⅱ diabetes. Methods A total of 72 elderly patients （ 65≥ year-old ） with acute coronary syndrome（ACS） were enrolled. After the loading doses of 300 mg clopidogrel and 300 mg aspirin, all patients received clopidogrel 75 mg/d and aspirin 100 mg/d. One week later, thrombelasto- graph determinations was used to determine the effect of clopidogrel and 〈50% was defined as CR, while the polymorphism of CYP2C19 gene was examined by PCR. The relationship between CYP2C19 polymorphism and the CR among the patients was investigated. Results Of the patients included, 19 （26.4%） were homEMs, 36 （50%） were hetEMs, and 17（23.6%） were PMs. The incidence of CR were 36.8%, 52.8% and 82.4% respectively （P〈 0.01 ）. Conclusion CYP2C19 gene polymorphism is associated with the risk of CR in elderly patients with type Ⅱ diabetes.
出处
《中国心血管病研究》
CAS
2012年第12期884-887,共4页
Chinese Journal of Cardiovascular Research
